FDA to Review AVT02, a High Concentration Biosimilar to Adalimumab
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
Ulcerative Colitis
Clinically Meaningful Improvements With Ozanimod in UC Trial
The True North study included patients with moderate to severe ulcerative colitis who had an inadequate response to prior treatment.
Prevalence of Adverse Pregnancy Outcomes Assessed With Biologics for IBD
The study aimed to determine the prevalence of adverse pregnancy outcomes associated with biologic use in women with IBD.
Results Mixed for Etrolizumab in Ulcerative Colitis
Etrolizumab is an investigational humanized monoclonal anti-ß7 antibody designed to selectively inhibit α4β7 and αEβ7 integrins.
Efficacy of Cannabinoids in Treating IBD Examined
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
Biosimilar Hulio Gets FDA Approval
The Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
Clinical Remission Observed With Ozanimod in Ulcerative Colitis Trial
Positive topline results were announced from the phase 3 True North trial evaluating the efficacy of ozanimod as an induction and maintenance therapy for adults with moderate to severe ulcerative colitis.
Filgotinib Associated With Clinical Remission in Ulcerative Colitis Study
At week 10, filgotinib 200mg met the primary end point with a significantly higher proportion of patients achieving clinical remission compared with placebo.
Adding Curcumin to Mesalamine May Benefit Patients With Ulcerative Colitis
“Given the minimal adverse events, we recommend that curcumin be considered as an adjunct to mesalamine in the treatment of UC.”
23andMe Develops Drug Compound Using Consumer Genetic Data
23andMe, a consumer genetics company, has licensed its first drug compound to Almirall, a global pharmaceutical company.
